ReviewFrontiers in immunology2021
The Role of Regulatory T Cells in Pulmonary Arterial Hypertension.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 51 citations in OpenAlex.
- Effects of immune checkpoint inhibitors on the pulmonary circulation in lung cancer patients.International journal of cancer · 2026Article
- Hypoxic microenvironment and pulmonary hypertension.Respiratory research · 2025Review
- Identification of Diagnostic Biomarkers Causally Associated With Gut Microbiota and Pulmonary Arterial Hypertension.Pulmonary circulation · 2025Article
- The role of lactate metabolism and lactylation in pulmonary arterial hypertension.Respiratory research · 2025Review
- Extracellular Vesicles as a Potential Biomarker of Pulmonary Arterial Hypertension in Systemic Sclerosis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Single-cell characterization of the immune heterogeneity of pulmonary hypertension identifies novel targets for immunotherapy.BMC immunology · 2025Article
- Deciphering the Complexities of Pulmonary Hypertension: The Emergent Role of Single-Cell Omics.American journal of respiratory cell and molecular biology · 2025Review
- Microbiome-Immune Interaction in Pulmonary Arterial Hypertension: What Have We Missed?Research (Washington, D.C.) · 2025Review
- Lymphocyte Involvement in the Pathology of Pulmonary Arterial Hypertension.International journal of molecular sciences · 2024Article
- Immunoregulatory Macrophages Modify Local Pulmonary Immunity and Ameliorate Hypoxic Pulmonary Hypertension.Arteriosclerosis, thrombosis, and vascular biology · 2024Article
- Infection and pulmonary vascular diseases consortium: United against a global health challenge.Pulmonary circulation · 2024Article
- Immunotherapy for Pulmonary Arterial Hypertension: From the Pathogenesis to Clinical Management.International journal of molecular sciences · 2024Review
- Bibliometric analysis of T-cells immunity in pulmonary hypertension from 1992 to 2022.Immunity, inflammation and disease · 2024Article
- Review
- IRF4 affects the protective effect of regulatory T cells on the pulmonary vasculature of a bronchopulmonary dysplasia mouse model by regulating FOXP3.Molecular medicine (Cambridge, Mass.) · 2024Article
- Pulmonary hypertension.Nature reviews. Disease primers · 2024Review
- Role of Treg cell subsets in cardiovascular disease pathogenesis and potential therapeutic targets.Frontiers in immunology · 2024Review
- Regulating the Regulators: Epigenetic Modulation of Regulatory T Cells in Pulmonary Hypertension.American journal of respiratory and critical care medicine · 2023Article
- Prostaglandin IAmerican journal of respiratory and critical care medicine · 2023Article
- Regulatory T lymphocytes as a therapy for ischemic stroke.Seminars in immunopathology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
Pulmonary arterial hypertension (PAH) is a chronic, incurable condition characterized by pulmonary vascular remodeling, perivascular inflammation, and right heart failure. Regulatory T cells (Tregs) stave off autoimmunity, and there is increasing evidence for their compromised activity in the inflammatory milieu of PAH. Abnormal Treg function is strongly correlated with a predisposition to PAH in animals and patients. Athymic Treg-depleted rats treated with SU5416, an agent causing pulmonary vascular injury, develop PAH, which is prevented by infusing missing CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.